Proteomics International Laboratories (PIQ) Q1 2027 TU earnings summary

Executive summary

• Exclusive Australian distribution agreement with Healius spans an initial three years, with a further three-year extension by mutual agreement; national rollout of Promarker D and Promarker Eso began 26 October 2026.

• Promarker Endo completed model refinement and independent Oxford validation post quarter end; Australian commercial availability is targeted for FY27 Q3, subject to deployment and regulatory requirements.

Financial highlights

• Net cash used in operating activities was $1.605m in the quarter; customer receipts were $264,000 and interest received was $36,000.

• Cash and cash equivalents were $1.831m at 30 September 2026, versus $3.5m at 30 June; a $2.0m FY26 R&D Tax Incentive refund arrived in October, lifting pro forma cash to $3.8m.

• Operating outflows included $700,000 for R&D, $574,000 for staff costs, $366,000 for administration and corporate costs, and $277,000 for manufacturing, operating, advertising and marketing costs.

Outlook and guidance

• Initial US distributor appointment targeted for FY27 H2; reimbursement work is focused on clinical and health-economic evidence in Australia and the US.

• Promarker Endo commercial availability is expected in FY27 Q3, conditional on clinical deployment, clinician reporting and follow-up guidance, and applicable quality, accreditation and regulatory requirements.